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Abstract 31 
Multiple pregnancy is a major cause of spontaneous preterm birth, which is related to uterine 32 
over-distention. The objective of this study was to determine whether an oxytocin receptor 33 
antagonist, retosiban (GSK221149A), inhibited the pro-contractile effect of stretch on human 34 
myometrium. Myometrial biopsies were obtained at term planned cesarean delivery (n=12). 35 
Each biopsy was dissected into 8 strips which were exposed in pairs to low or high stretch 36 
(0.6g or 2.4g) in the presence of retosiban (1 µM) or vehicle (DMSO) for 24 hours. 37 
Subsequently, we analysed the contractile responses to KCl and oxytocin in the absence of 38 
retosiban. We found that incubation under high stretch in vehicle alone increased the 39 
response of myometrial explants to both KCl (P=0.007) and oxytocin (P=0.01). However, 40 
there was no statistically significant effect of stretch when explants were incubated with 41 
retosiban (P=0.3 and 0.2, respectively). Incubation with retosiban in low stretch had no 42 
statistically significant effect on the response to either KCl or oxytocin (P=0.8 and >0.9, 43 
respectively).Incubation with retosiban in high stretch resulted in a statistically significant 44 
reduction (median fold change, inter-quartile range, P) in the response to both KCl (0.74, 45 
0.60-1.03, P=0.046) and oxytocin (0.71, 0.53-0.91, P=0.008). The greater the effect of 46 
stretch on explants from a given patient, the greater was the inhibitory effect of retosiban (r= 47 
-0.65, P=0.02 for KCl and r= -0.73, P=0.007 for oxytocin). These results suggest that 48 
retosiban prevented stretch-induced stimulation of human myometrial contractility. Retosiban 49 
treatment is a potential approach for preventing preterm birth in multiple pregnancy. 50 
51 
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Introduction  52 
 53 
Multiples account for 1-2% of all births but account for more than 30% of neonatal deaths 54 
due to preterm birth (1). Overall, approximately 60% of multiples deliver before 37 weeks 55 
gestation and 8% before 32 weeks (2). There is currently no effective intervention in 56 
preventing preterm delivery in twins as progesterone (3), cervical cerclage (4), and cervical 57 
pessary (5) have failed to show any benefit. Uterine over-distention is believed to explain the 58 
increased rate of preterm labour in multiple pregnancies (6). Mechanical stretch has been 59 
shown to increase myometrial gap junctions (7) and other inflammatory signalling proteins 60 
(8) in animal experiments. In human samples, prolonged exposure of explants to mechanical 61 
stretch stimulates myometrial contractility (9) and stretch of isolated cells up-regulates the 62 
human oxytocin receptor (10), which is known to have a crucial role in parturition.  63 
Retosiban (GSK221149A) is a novel, non peptide, orally active oxytocin receptor antagonist. 64 
It has sub-nanomolar affinity for the oxytocin receptor (Ki=0.65nM) with >1400-fold selectivity 65 
over the closely related vasopressin receptors (11). A recently published phase 2 proof-of-66 
concept study used intravenous retosiban for the treatment of spontaneous preterm labour 67 
and showed a favourable efficacy and safety profile (12). However, no studies to date have 68 
used retosiban or other oxytocin receptor antagonists for the prevention of preterm labor in 69 
high risk pregnancies, i.e. as prophylaxis in women at high risk. This is likely because 70 
atosiban, which is the only oxytocin receptor antagonist currently licensed in Europe (not in 71 
USA), can only be given as a continuous intravenous infusion which makes long term 72 
administration impractical. In contrast, retosiban can be given orally and could feasibly be 73 
given over a prolonged period of time as a preventative treatment. This approach would be 74 
of particular value in multiple pregnancy due to the lack of other effective preventative 75 
approaches. Therefore, the objective of the present study was to determine whether 76 
retosiban could inhibit the stimulatory effect of mechanical stretch on human myometrial 77 
explants.  78 
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Materials and Methods 79 
 80 
Tissue collection  81 
Human myometrial samples were obtained from non-labouring patients, undergoing routine 82 
elective cesarean section at term. The specimens were taken from the upper edge of the 83 
lower segment uterine incision following the delivery of the baby and the placenta and were 84 
placed into Krebs’s solution (119 mM NaCL, 4.7 mM KCl, 1.2 mM MgSO4, 26 mM NaHCO3, 85 
1.2 mM KH2PO4, 2.5 mM CaCl2, 11.1 mM D-glucose) as previously described (13). All 86 
patients gave their informed, written consent to participate and the study was approved by 87 
the Cambridge Research Ethics Committee. The indication for cesarean section was prior 88 
cesarean section in all 12 cases, and it was carried out between 38-39 complete weeks’ 89 
gestation. All women were either in their second or third pregnancy, the mean maternal age 90 
was 32.7 years (standard deviation [SD]: 4.4 yrs), and the mean birth weight was 3518 91 
grams (SD: 295g). Multiple pregnancies and pregnancies with maternal complications were 92 
excluded. As we explain below the maternal characteristics did not affect the analyses. 93 
 94 
Myometrial explant culture and experimental design 95 
Each uterine biopsy was cleared of the serosa, fibrous tissue and blood vessels and 96 
dissected into 8 longitudinal strips of approximately 2-3 x 8-12mm. The strips were 97 
maintained in culture medium (Phenol red free DMEM supplemented with 10% charcoal 98 
stripped fetal calf serum, 2 mM L-glutamine, and antibiotics) using the method previously 99 
described (13). The strips from each biopsy were separated in four pairs and each pair was 100 
incubated under the same conditions. Half of the strips were suspended under either low 101 
tension (0.6 g mass) or high tension (2.4 g mass). The choice of these relative tensions and 102 
the strengths of this model to study the effect of stretch have been described in detail 103 
previously (9,13). Similarly, half of the strips were incubated with 1µM of retosiban, which 104 
had been disolved in DMSO and stored at 4°C in 10 mM aliquots, and half with vehicle 105 
(same concentration of DMSO). Consequently, the four experimental groups were: low 106 
6 
 
tension with retosiban, low tension with vehicle, high tension with retosiban, and high tension 107 
with vehicle. All comparisons between groups were paired analyses on samples from the 108 
same patient. Hence, maternal characteristics did not affect the analyses.  109 
 110 
Isometric tension measurements  111 
Following 20-24 hours of incubation (37°C, humidified, 5% CO2 incubator), the strips were 112 
transferred to an 8-chamber organ bath for isometric tension studies. The strips were 113 
washed as described below in order to remove any residual retosiban from the tissue. All the 114 
experiments in the organ bath were done in the absence of retosiban. Myometrial 115 
contractility was studied using the previously described protocol (13). Tension was initially 116 
set at 2g for all strips. Strips were washed with fresh buffer after 15 and 30 min and the 117 
tension reset to 2g. After a further hour of washes (every 15min), strips were exposed to 118 
50mM KCl for 5-7min. This was washed out, the tissue allowed to recover and then a 119 
cumulative concentration response curve to oxytocin (up to 100 nM) was obtained. For 120 
analysis of contractility after explant culture, maximal responses to KCl and oxytocin 121 
(measured in g) were normalized to strip wet weight (also measured in g) to produce a 122 
normalized response, as previously described (13).  123 
 124 
The mean normalized responses of duplicate strips were calculated for the four different 125 
groups. Effects were expressed as fold change, i.e. the ratio of the mean normalised 126 
responses in the experimental and control conditions from different strips obtained from the 127 
same woman. pEC50 values (i.e. negative log10 of the interpolated molar concentration of 128 
oxytocin causing 50% of the maximal response) were calculated using analysis of the area 129 
under the curve for each concentration to oxytocin, as previously described (13). 130 
 131 
Data analysis 132 
Since the data were expressed as fold changes, all ratios were log transformed (14) and the 133 
normality of the distribution of the ratios following log transformation was assessed using the 134 
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Shapiro-Wilk test. All statistical tests were one sample Student’s t-tests that the mean fold 135 
change was significantly different from one (i.e. all analyses were paired comparisons of 136 
different strips from the same woman and a ratio of one indicated no effect). Continuous 137 
associations were assessed using Pearson's correlation co-efficient between log 138 
transformed fold changes. Student’s paired t-test was used to compare the pEC50 from 139 
different exposures. The n in the text refers to the number of independent experiments 140 
performed, using tissue from separate donors. Statistical significance was assumed at 141 
P<0.05 (two sided).   142 
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Results 143 
Effect of stretch on myometrial contractility in tissues incubated with retosiban or 144 
vehicle 145 
Stretch under high tension increased the contractility of tissues that were not incubated with 146 
retosiban (Figure 1). The median fold changes (IQR, P) with stretch (high tension compared 147 
with low tension) were 1.59 (1.14-1.81, P= 0.007, n=12) and 1.51 (1.04-1.82, P=0.01, n=12) 148 
for KCl and oxytocin, respectively. There was no statistically significant effect of stretch when 149 
strips were incubated with retosiban (Figure 1). The median fold changes were 1.14 (0.97-150 
1.27, P=0.27, n=12) for KCl and 1.14 (0.94-1.34, P=0.23, n=12) for oxytocin. 151 
 152 
Effect of incubation with retosiban in low and high stretch 153 
In tissues stretched under low tension, incubation with retosiban had no statistically 154 
significant effect on the response to either KCl or oxytocin (Figure 1). The median fold 155 
changes (IQR, P) with retosiban were 1.00 (0.85-1.22, P=0.81, n=12) for KCl and 0.97 (0.76-156 
1.07, P=0.15, n=12) for oxytocin. In tissues stretched under high tension, incubation in 157 
retosiban resulted in a statistically significant reduction in the response to both KCl and 158 
oxytocin (Figure 1). The median fold changes were 0.74 (0.60-1.03, P=0.046, n=12) for KCl 159 
and 0.71 (0.53-0.91, P=0.008, n=12) for oxytocin. 160 
 161 
Relationship between the effect of stretch and the effect of retosiban 162 
We noted that there was significant variation in the magnitude of reduction in responses to 163 
KCl and oxytocin induced by incubation in retosiban. We found that the greater the effect of 164 
stretch on responses of myometrium from a given patient, the greater was the reduction in 165 
response induced by retosiban (Figure 2). 166 
 167 
Effect of stretch on the pEC50 to oxytocin 168 
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The sensitivity of the myometrium to oxytocin was estimated using the pEC50. Stretch had no 169 
significant effect on the pEC50 to oxytocin in the presence of either retosiban or vehicle. In 170 
tissues incubated with retosiban, the median pEC50 values (IQR) for oxytocin were 8.43 171 
(8.22-8.68) in low stretch and 8.65 (8.34-8.71) in high stretch (P=0.51, n=10). In tissues 172 
incubated with vehicle, the pEC50 values for oxytocin were 8.90 (8.77-9.04) in low stretch 173 
and 9.08 (8.86-9.22) in high stretch (P=0.17, n=11).  174 
 175 
Effect of retosiban on the pEC50 to oxytocin in similarly stretched tissues 176 
Retosiban reduced the sensitivity to oxytocin in both conditions of low tension and high 177 
tension (Figure 3). When incubated under low stretch, the pEC50 to oxytocin in samples 178 
incubated in retosiban was 8.36 (8.21-8.68) and in samples incubated in vehicle was 8.93 179 
(8.66-9.07) (P=0.001, n=11). When incubated under high stretch, the pEC50 to oxytocin in 180 
samples incubated in retosiban was 8.67 (8.34-8.71) and in samples incubated in vehicle 181 
was 9.16 (8.97-9.22) (P<0.001, n=9).   182 
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Discussion 183 
 184 
We had previously demonstrated that prolonged stretch of human myometrial strips under 185 
high tension resulted in increased myometrial contractility (9) and we replicated this 186 
observation in the present study. The main new finding of the present analysis is that this 187 
stimulatory effect of prolonged mechanical stretch was prevented by incubation in the novel, 188 
non-peptide, orally active oxytocin receptor antagonist, retosiban (GSK221149A). 189 
 190 
This effect of retosiban cannot be explained by the presence of residual drug still being 191 
present at the time of the contractility experiments. First, the tissues were washed 8 times in 192 
total over the 2 hours between being removed from incubation in retosiban to their first 193 
exposure to oxytocin. As retosiban is a competitive antagonist of the oxytocin receptor (i.e. it 194 
does not covalently bind with the oxytocin receptor), we would anticipate that there would be 195 
minimal levels of the drug present when the myometrial contractility experiments were 196 
performed. Furthermore, prolonged incubation in retosiban reduced the response of the 197 
myometrium to both oxytocin and potassium chloride. The latter stimulates myometrial 198 
contraction by depolarisation of the smooth muscle, with resulting influx of calcium into the 199 
intra-cellular space. As this pathway does not involve the oxytocin receptor, presence of 200 
residual retosiban cannot explain the reduced response to potassium.  201 
 202 
We interpret the data as indicating that prolonged exposure to retosiban had an effect on the 203 
intracellular pathways controlling myometrial contractility. However, this effect appears to be 204 
specific to tissues maintained under high tension, as it was not observed in strips maintained 205 
under low tension. One possible explanation for the pattern observed is that stretch of 206 
myometrium under high tension induces constitutive activation of the oxytocin receptor and 207 
that, in the presence of this constitutive activation, an inverse agonist property of retosiban 208 
can be observed. It is well recognised that antagonists can also be inverse agonists and that 209 
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inverse agonist effects may only be observed under specific conditions, as the given 210 
receptor has to be constitutively active for an inverse agonist to have an effect (15). 211 
Importantly, inverse agonist effects are observed when tissues are incubated in the given 212 
drug in the absence of the endogenous agonist of the receptor. For example, previous 213 
studies have shown that effects of the AT1 receptor antagonist/inverse agonist, olmesartan, 214 
in cultured cardiomyocytes were dependent on mechanical stress, and that this was due to 215 
constitutive activation of the AT1 receptor by stretch (16). We also observed a stretch 216 
independent effect of retosiban, namely, that incubation in the drug was associated with a 217 
decrease in the pEC50 to oxytocin, irrespective of the degree of stretch. The pEC50 can be 218 
used as an approximation for the affinity of the receptor for an agonist. However, the pEC50 219 
can also be influenced by other factors, e.g. binding of other proteins within the cell to the 220 
given receptor. Collectively, these observations indicate complex inter-relationships between 221 
stretch, the oxytocin receptor and myometrial contractility, and further studies will be 222 
required to delineate the mechanisms underlying the current findings.  223 
 224 
The current study indicates a potential new therapeutic approach to the problem of preterm 225 
birth in multiple pregnancy. Pharmacological approaches to this clinical challenge have 226 
focused on the use of progestogens, which are effective treatments in high risk singleton 227 
pregnancies. However, treatment with progestogens does not prolong pregnancy or improve 228 
perinatal outcome in twin pregnancies (3). The evidence supporting this negative statement 229 
is strong: the meta-analysis includes more than 3500 patients in total, and the quality of the 230 
trials was high (3). The difference between high risk singletons and multiples in relation to 231 
progestogens may reflect different etiologies of preterm birth. It has been shown that there 232 
are significant differences in the contractility of myometrium obtained from singleton and twin 233 
pregnancies, and that the contractile activity correlates with the increasing level of stretch 234 
(17). It has also previously been demonstrated that progesterone does not inhibit stretch-235 
induced changes of human myometrial gene expression (18). Hence, the lack of effect of 236 
progesterone on the risk of preterm birth in twins could be explained by stimulation of 237 
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myometrial contractility by stretch through a progesterone insensitive mechanism. The 238 
current data suggest that the oxytocin receptor may be a better target for pharmacological 239 
approaches to prevent preterm birth in multiple pregnancy. However, this hypothesis will 240 
require direct testing in clinical studies.  241 
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Figure legends 307 
 308 
Figure 1: The effect of stretch and retosiban on maximal contractile responses to KCl and 309 
oxytocin in human, pregnant, non-labouring myometrium. Strips of myometrium were 310 
incubated under low tension (0.6g) or high tension (2.4g) in the presence of retosiban (1µM) 311 
or vehicle (DMSO) as described in methods.  312 
A, a representative set of traces (in which the fold change in maximal KCl response with 313 
retosiban was closest to the median value) showing the effect of incubation with retosiban on 314 
the contractile responses of myometrial strips stretched under high tension to both KCL 315 
(50mM) and increasing doses of oxytocin (up to 100nM). Dashed lines represent incremental 316 
half log doses. These traces were derived from two strips of the same biopsy. The upper 317 
strip was incubated under 2.4g of tension with retosiban and the lower strip was incubated 318 
under 2.4g of tension with vehicle alone.  319 
B, The effect of stretch on maximal contractile responses to KCl (circles) and oxytocin 320 
(squares) in human pregnant myometrium incubated with retosiban (black) or vehicle 321 
(white). Maximum responses (in grams) were expressed relative to the wet weight of each 322 
strip to produce a normalized response. Mean normalized responses from duplicate strips 323 
were compared and the fold change induced by stretch were compared. Each data point 324 
represents the fold change from one biopsy (the y axis is presented in log scale). The 325 
normality of the above distributions was tested using the Shapiro-Wilk test after the log-326 
transformation (P= 0.28, 0.32, 0.84, and 0.99 respectively). The P-values presented on the 327 
figure were calculated using Student’s paired t-test. 328 
C, The effect of retosiban on maximal contractile responses to KCl and oxytocin in human 329 
pregnant myometrium incubated under low (white) or high tension (black). Fold changes with 330 
retosiban were compared as above. The normality of the distributions was tested as above 331 
(P= 0.37, 0.36, 0.94, and 0.99 respectively). 332 
Bars indicate median fold change in the given experimental group. 333 
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 334 
Figure 2. Correlation between the effect of stretch and the effect of retosiban: A. KCl, B. 335 
Oxytocin. Each point is the fold change induced by stretch (X axis) and the fold change 336 
induced by retosiban in high stretch (Y axis) derived from the myometrial explants obtained 337 
from a given woman. The correlation coefficient (r) and P values were calculated after log-338 
transformation of the fold changes. The r for KCl was -0.65 and for oxytocin -0.73 (both 339 
n=12). The r2 represents the proportion of the inter-patient variability in response to retosiban 340 
which can be explained by variation in response to stretch. 341 
 342 
Figure 3. Effect of retosiban on the pEC50 to oxytocin in similarly stretched tissues: A. Low 343 
tension, B. High tension. Each point is the pEC50 to oxytocin from the myometrium of a given 344 
woman. Each line connects the pEC50 values derived from the myometrium of the same 345 
woman. The pEC50 values were calculated using analysis of the area under the curve for 346 
each concentration to oxytocin. The P-values were calculated using Student’s paired t-test.  347 
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